Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2019-07-14 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Reports Positive Phase III Meeting with the FDA 4 pages 181.7KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Telix Pharmaceuticals about a positive Phase III meeting with the FDA regarding their clinical trial and regulatory strategy for a drug candidate. It discusses regulatory consultation outcomes, clinical trial design, manufacturing data, and plans for submission of a Biologics License Application (BLA). The content focuses on regulatory and clinical development updates rather than financial results, management changes, or shareholder voting. It is not a full financial report, earnings release, or management discussion. The document is longer than 5,000 characters and contains substantive information about regulatory progress and clinical trial plans, which is typical of a Capital/Financing Update or Regulatory Filing. However, since it primarily concerns regulatory interactions and clinical trial progress rather than financing or capital structure changes, the best fit is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. Confidence is high given the detailed regulatory content and absence of financial data or other report types.
2019-07-14 English
Trading Halt 2 pages 297.2KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Telix Pharmaceuticals Limited regarding a trading halt requested pending an announcement about a proposed capital raise. It is dated 15 July 2019 and explicitly states the halt is requested until the announcement of the capital raise or normal trading resumes. The content is brief (1823 characters) and does not contain financial statements or detailed financial data. It is an announcement related to capital/financing activity but does not itself provide the financing update or details. According to the rules, such a brief announcement about a trading halt pending a capital raise announcement is best classified as a Capital/Financing Update (CAP).
2019-07-14 English
Telix and Grupo RPH LATAM Manufacturing and Distribution 3 pages 187.4KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a manufacturing and distribution agreement between Telix Pharmaceuticals and Grupo RPH for the LATAM region. It focuses on the business partnership, product distribution, and market expansion. There are no financial statements, regulatory filings, voting results, or detailed financial data. The content is an announcement of a capital/financing or business development update rather than a report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP). The document length is moderate and contains detailed business agreement information, not a report or transcript.
2019-07-02 English
Telix and PI Medical Distribution Agreement for Netherlands 3 pages 185.0KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a distribution agreement between Telix Pharmaceuticals and PI Medical for the Netherlands. It details the commercial partnership and distribution rights for a specific product (TLX591-CDx) but does not contain financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any form of financial or regulatory filing. The content is a corporate announcement about a commercial agreement, which fits best under Capital/Financing Update (CAP) as it relates to business development and commercial arrangements impacting the company's capital or market presence.
2019-07-01 English
CEO presentation to Macquarie Emerging Leaders Conference 25 pages 3.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from the Emerging Leaders Forum dated 19th June 2019, focusing on Telix Pharmaceuticals Limited. It includes company background, clinical pipeline, market opportunities, financial snapshot, milestones, and management biographies. The content is structured as a comprehensive investor presentation with forward-looking statements, clinical trial updates, market data, and strategic outlook. There are no indications that this is an official annual or interim report, audit report, or regulatory filing. It is not a transcript of a call, nor a voting or dividend announcement. The document is too long and detailed to be a simple announcement or report publication notice. The presence of slides, forward-looking statements, and detailed business and financial information aligns with the definition of an Investor Presentation (IP).
2019-06-18 English
Telix and Monrol Manufacturing and Distribution Agreement 3 pages 242.5KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a manufacturing and distribution agreement between Telix Pharmaceuticals and Eczacıbaşı-Monrol. It details the terms of the agreement, the strategic importance, and background information about the companies and products involved. There is no financial data, regulatory filing, or report content such as annual or quarterly financial statements. The document is an announcement of a business partnership and commercial arrangement, not a financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, and can also include significant commercial agreements impacting company operations and market reach.
2019-06-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.